Aclaris Therapeutics Announces Global License Agreement With Biosion, $80 Million Private Placement
November 20, 2024
November 20, 2024
PALO ALTO, California, Nov. 20 -- Cooley, a law firm, issued the following news release:
Reston - November 18, 2024 - Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.
Under the terms of the agreement, Aclaris will grant Biosion worldwide rights (excluding Greater China) to BSI- . . .
Reston - November 18, 2024 - Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.
Under the terms of the agreement, Aclaris will grant Biosion worldwide rights (excluding Greater China) to BSI- . . .